Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice. (2022)
Attributed to:
Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/brain/awab246
PubMed Identifier: 34196695
Publication URI: http://europepmc.org/abstract/MED/34196695
Type: Journal Article/Review
Volume: 145
Parent Publication: Brain : a journal of neurology
Issue: 1
ISSN: 0006-8950